NCT01416324View on ClinicalTrials.gov

First Time in Human Study Using GSK2330672

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 15, 2011

Primary Completion Date

September 9, 2011

Study Completion Date

September 9, 2011

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

placebo

Vehicle used to dilute the powder for oral administration.

DRUG

0.1 mg GSK2330672

GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

DRUG

0.3 mg GSK2330672

GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

DRUG

1 mg GSK2330672

GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

DRUG

3 mg GSK2330672

GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

DRUG

10 mg GSK2330672

GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

DRUG

30 mg GSK2330672

GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

DRUG

60 mg GSK2330672

GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.

Trial Locations (1)

55404

GSK Investigational Site, Minneapolis

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01416324 - First Time in Human Study Using GSK2330672 | Biotech Hunter | Biotech Hunter